Progress against follicular lymphoma.
Progress against follicular lymphoma.
复制标题
DOI：
10.1097/moh.0b013e3283622ed6
复制
发表时间：
2013-07
影响因子：
3.2
通讯作者：
Wendel HG
中科院分区：
文献类型：
--
作者：
Schatz JH;Oricchio E;Puvvada SD;Wendel HG
我们希望分享滤泡性淋巴瘤(FL)研究和新疗法的最新进展，并强调改善FL治疗的令人兴奋的机会。滤泡性淋巴瘤在某种程度上被研究界忽视了，但最近的基因组研究已经确定了FL的关键遗传损害。此外，一种新的小鼠模型可用于探索这些病变在FL的发生、发展和治疗中的作用。此外，现在有新的小分子抑制剂可以靶向FL的关键通路，包括B细胞受体信号转导和组蛋白修饰物。淋巴瘤是一种非常常见且仍无法治愈的淋巴瘤。然而，最近的基因组和体内生物学研究开始揭示FL的分子驱动因素。这与针对关键靶点的有效小分子抑制剂的开发不谋而合。总而言之，这些进展表明，我们正处于FL治疗的一个早该到来的分水岭时刻。
We wish to share recent progress in research and new therapies against follicular lymphoma (FL) and highlight exciting opportunities to improve the treatment of FL. Follicular lymphoma has been somewhat neglected by the research community, but recent genomic studies have identified key genetic lesions in FL. In addition, a new murine model is available to explore the function of these lesions in development, progression, and treatment of FL. Moreover, new small molecule inhibitors are now available that target key pathways in FL including B-cell receptor signaling and histone modifiers. FL is a very common and still incurable form of lymphoma. However recent genomic and in vivo biological studies are beginning to unveil the molecular drivers of FL. This coincides with the development of effective small molecule inhibitors against key targets. Together these developments suggest that we are at a long overdue watershed moment in the treatment of FL.